EUVIMEDEUVIMED entdecken
Kommentar

The role of papillary muscle abnormalities in hypertrophic cardiomyopathy: a new paradigm shift?

Alexandra Toste, Nuno Cardim iD

European Heart Journal - Cardiovascular Imaging · 2023

DOI: 10.1093/ehjci/jead115 ↗

Kurz gefasst

Kommentar in der Zeitschrift European Heart Journal - Cardiovascular Imaging, 2023. Verfasst von Alexandra Toste und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hospital da Luz Cardiology Department Av Lusíada, 100 1500-650 Lisbon, Portugal. Hauptthemen laut MEDLINE: Apical Hypertrophic Cardiomyopathy, Cardiomyopathy, Hypertrophic, Mitral Valve Insufficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This editorial refers to ‘Apical papillary muscle displacement is a prevalent feature and a phenotypic precursor of apical hypertrophic cardiomyopathy’, by D. Filomena et al., https://doi.org/10.1093/ehjci/jead078. Hypertrophic cardiomyopathy (HCM) has been known as the most common genetic heart disease, with an estimated prevalence of 1:2001 in the general population. From the molecular point of view, it is a very heterogeneous disease, with pathogenic variants described in almost all sarcomere proteins, mainly with autosomal dominant (AD) transmission.2 The diagnostic power of current genetic testing is modest, identifying a causal gene in approximately half of HCM patients.2 Clinical diagnosis of HCM is based on otherwise unexplained left ventricular hypertrophy, which may present in a wide variety of patterns.3 Hypertrophic cardiomyopathy phenotypic heterogeneity may also involve the mitral valve and its apparatus, whose abnormalities, depicted by cardiac magnetic resonance (CMR), are a very common finding among HCM patients. Mitral valve abnormalities include leaflet and/or chordal elongation, dysplasia and prolapse, and laxity and hypermobility.3 Papillary muscle (PM) abnormalities include anterior and/or apical displacement, hypertrophy, bifidity, presence of accessory PM, and direct insertion into the anterior mitral valve leaflet.4 Altogether, these factors may contribute to left ventricular outflow tract (LVOT) obstruction and should be addressed, in addition to septal hypertrophy, when treating obstructive HCM patients. In fact, patients with HCM with abnormal PM seem to have a higher degree of the resting LVOT gradient, which may be independent of septal thickness.5

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apical Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicMitral Valve InsufficiencyHumansPapillary Muscles

Autor:innen und Institutionen

  • Hospital da Luz Cardiology Department Av Lusíada, 100 1500-650 Lisbon, Portugal.
  • Nova Medical School, Campo Mártires da Patria 130, 1169-056 Lisbon, Portugal.
  • Cardiology Department Hospital CUF- Descobertas, Rua Mário Botas, 1998-018 Lisbon, Portugal.

ORCID-Profile: Nuno Cardim

Zitieren

APA

Toste, A., & Cardim, N. (2023). The role of papillary muscle abnormalities in hypertrophic cardiomyopathy: a new paradigm shift?. European Heart Journal - Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jead115

Vancouver

Toste A, Cardim N. The role of papillary muscle abnormalities in hypertrophic cardiomyopathy: a new paradigm shift?. European Heart Journal - Cardiovascular Imaging. 2023. doi:10.1093/ehjci/jead115

BibTeX
@article{Toste2023,
  author = {Toste, Alexandra and Cardim, Nuno},
  title = {The role of papillary muscle abnormalities in hypertrophic cardiomyopathy: a new paradigm shift?},
  journal = {European Heart Journal - Cardiovascular Imaging},
  year = {2023},
  doi = {10.1093/ehjci/jead115}
}
Kostenlos starten →